Subscribe
dna-1
vitstudio / shutterstock.com
17 January 2017Biotechnology

Horizon Discovery expands CRISPR licence

UK-based Horizon Discovery has broadened its gene editing capabilities through the amendment of a pre-existing licence with ERS Genomics to include the full commercial rights for the use of CRISPR.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Horizon partners with big pharma company on CRISPR
29 August 2018   UK-based Horizon Discovery has entered into a CRISPR collaboration with an unnamed big pharma company.
Europe
Horizon Discovery expands CRISPR licence with ERS Genomics
5 December 2017   UK-based genomics company Horizon Discovery has expanded its licence coverage for use of the CRISPR gene-editing technology.


Editor's picks

Explainer: ARIPO’s role in Plant Variety Protection
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025

Editor's picks

Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025

More on this story

Big Pharma
Horizon partners with big pharma company on CRISPR
29 August 2018   UK-based Horizon Discovery has entered into a CRISPR collaboration with an unnamed big pharma company.
Europe
Horizon Discovery expands CRISPR licence with ERS Genomics
5 December 2017   UK-based genomics company Horizon Discovery has expanded its licence coverage for use of the CRISPR gene-editing technology.

More on this story

Big Pharma
Horizon partners with big pharma company on CRISPR
29 August 2018   UK-based Horizon Discovery has entered into a CRISPR collaboration with an unnamed big pharma company.
Europe
Horizon Discovery expands CRISPR licence with ERS Genomics
5 December 2017   UK-based genomics company Horizon Discovery has expanded its licence coverage for use of the CRISPR gene-editing technology.

More features

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Explainer: ARIPO’s role in Plant Variety Protection
J&J sues over schizophrenia drug generic following patent victory
WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids